What changed for Macular Degeneration
A plain English summary of what recently moved in the public data Voxsanity tracks for Macular Degeneration. Updated from government registries. Not medical advice.
How to read these changes: every figure on this page is the difference between two snapshots of what Voxsanity had tracked on each date. Voxsanity only began taking daily snapshots in July 2026 and is still ingesting the public registries, so a rise here is mostly our own coverage expanding rather than new research appearing. Read it as our tracked coverage growing, not as a claim about real-world research changing this fast: it overstates how much actually changed.
Comparing the two most recent snapshots, 27 July 2026 and 28 July 2026.
- Trials recruiting at Australian sites 17 to 16 (-1)
- Trials recruiting worldwide 186 to 185 (-1)
- Trials on record 1,460 to 1,454 (-6)
Newly subsidised on the PBS
No PBS-reviewed medicines are tracked for Macular Degeneration yet, so new PBS listings cannot be reported for it. This is a gap in what Voxsanity has mapped, not a statement that no medicines are subsidised — check the PBS directly.
Past updates
Tracking began in July 2026. Month on month changes will appear here once a second month of data has been recorded. Until then, the comparison above shows the most recent movement.
Recent trend
Weekly, most recent weeks (fills out to a monthly trend as history grows).
Recent trial results
The 30 most recent of 77 trials tracked for Macular Degeneration that have reported results to a public registry.
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
-
NCT05536297 · results posted 14 April 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT05536297) enrolled a total of 278 participants across three groups. One group (64 people) received a treatment called ACP every month throughout the whole study. A second group (62 people) had previously received ACP on a mixed schedule — sometimes every month, sometimes every other month — and then switched to receiving it every month. A third group (152 people) had previously received a sham (inactive/dummy) treatment and then switched to receiving ACP every month. The trial was primarily measuring how many participants...
Read the full trial page · View reported results on ClinicalTrials.gov ↗
-
NCT03364153 · results posted 12 March 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT03364153) enrolled 121 people with an eye condition affecting the retina. Sixty-one participants received injections of a drug called avacincaptad pegol, and 60 received a sham (dummy) procedure as a comparison group. The trial ran for 18 months and was primarily measuring how quickly a specific area of damage at the back of the eye — called the ellipsoid zone defect — grew over time. Secondary measurements included changes in vision sharpness and the eye's sensitivity to light. The reported data shows that, for the main...
-
NCT04777201 · results posted 24 October 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled a total of 1,146 participants across three groups. The main study included 524 people who had previously been treated with a medicine called faricimab (Cohort A) and 505 people who had previously been treated with a different medicine called aflibercept (Cohort B); both groups then continued on faricimab using a personalised dosing approach. A separate smaller sub-study ran at the same time and included 117 additional participants who also received faricimab. The trial was primarily tracking what types of unwanted hea...
-
NCT05265624 · results posted 1 October 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 80 people in total, split into two groups: 60 people who received their genetic risk results early ("Early Genetic Results Disclosure") and 20 people who received them later ("Late Genetic Results Disclosure"). The trial was measuring whether learning about your personal genetic risk influenced levels of carotenoids — natural compounds found in fruit and vegetables — in the body. Carotenoid levels were tracked over 12 months using several different methods: a skin scan using light reflection, a second skin scan using...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05019521 · results posted 5 September 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT05019521) studied a medicine called danicopan in people with geographic atrophy — a form of age-related macular degeneration where patches of the retina gradually break down, causing vision loss. Participants were randomly assigned to receive one of three doses of danicopan (100 mg twice daily, 200 mg twice daily, or 400 mg once daily) or a placebo (a dummy pill with no active medicine). In the first 52-week period, 93, 91, 91, and 90 people started in each of those groups respectively. After that, participants who had bee...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04437368 · results posted 12 August 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04437368) enrolled 98 people in total across three groups: 52 people received a lower dose of an investigational gene therapy called GT005, 9 received a higher dose, and 37 were in an untreated control group. The trial was looking at a condition called geographic atrophy (GA) — a progressive eye condition where patches of cells in the back of the eye gradually die off. The main thing being measured was how much those damaged patches grew over time, specifically the change in their size (measured in square millimetres) from...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04757636 · results posted 5 August 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 998 people in total across three groups. All participants had a condition called neovascular age-related macular degeneration (nAMD) — a form of macular degeneration where abnormal blood vessels grow at the back of the eye. One group received a drug called OPT-302 on a standard schedule alongside another eye injection called aflibercept; a second group received the same combination but on a less frequent (extended) schedule; and a third group received aflibercept plus a sham (dummy) injection instead of OPT-302. The t...
-
NCT04757610 · results posted 22 July 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 986 people in total across three groups, all of whom had a condition called neovascular age-related macular degeneration (nAMD) — a form of age-related macular degeneration that can affect central vision. One group (329 people) received a combination of the drug ranibizumab plus OPT-302 on a standard injection schedule; a second group (326 people) received the same combination but on a less frequent ("extended") schedule; and a third group (331 people) received ranibizumab plus a sham (dummy) injection. The main thing...
-
NCT04566445 · results posted 10 July 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04566445) enrolled 255 people in total across three groups: 87 received a medium dose of a gene therapy called GT005, 86 received a high dose of GT005, and 82 received no treatment (the untreated control group). The trial was studying geographic atrophy — a progressive condition where patches of cells at the back of the eye break down and grow over time — and was measuring how much those patches grew over roughly 72 weeks (about 18 months) as its main goal, with further measurements taken out to 96 weeks (about two years)....
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT06785090 · results posted 6 May 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 87 people who had recently undergone cataract surgery — 45 in the bromfenac group (who received bromfenac eye drops) and 42 in a control group (who did not receive the drops). All 87 participants completed the study with no dropouts. The trial was primarily measuring changes in the thickness of the macula — a small but important area at the back of the eye — using a scanning technology called Optical Coherence Tomography (OCT), which takes detailed images of eye tissue. Measurements were taken before surgery and again...
-
NCT04774926 · results posted 24 February 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04774926) enrolled 122 people, all of whom received a medicine called brolucizumab (6 mg). The trial was designed to look at an eye condition involving abnormal blood vessel growth beneath the retina (the light-sensitive layer at the back of the eye). The main thing the trial was trying to understand was whether certain patient characteristics at the start of the trial could predict which patients would end up completely free of fluid in their retina after about 48 weeks of treatment — receiving injections every 12 weeks....
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03478878 · results posted 3 July 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 9 people in total — 7 in Cohort 1 and 2 in Cohort 2. All 9 participants completed the trial with no drop-outs. The trial was measuring changes in how quickly participants' eyes adjusted to the dark (called "rod intercept time," or RIT — the time it takes for the eye's light-sensitive cells to kick in after moving from a bright to a dark environment). It also measured how many letters participants could read under dim light conditions, and asked participants to fill in a questionnaire about how well they managed everyd...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04239027 · results posted 4 June 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04239027) enrolled 210 people, all of whom received a medicine called brolucizumab (also known as RTH258). The trial was looking at a condition affecting the back of the eye, specifically abnormal blood vessel growth under the retina (called choroidal neovascularisation, or CNV). Researchers used a specialised eye scan — a non-invasive imaging technique that photographs blood flow in the eye without dye injections — to measure the size of these abnormal blood vessel areas over roughly one year (48 weeks). By the end of the...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04597632 · results posted 4 April 2024
According to the results reported on ClinicalTrials.gov, this extension study enrolled 248 participants, all of whom received the eye injection brolucizumab 6 mg. Of these, 231 completed the study and 17 did not. The trial was measuring how well participants' vision held up over time, how thick the central part of the retina (the light-sensitive layer at the back of the eye) was, and how long doctors were able to go between treatment appointments without seeing signs of active disease returning in the eye. The reported data shows that, on average, participants' vision scores (measured by how...
-
NCT04864834 · results posted 26 March 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04864834) enrolled 485 adults in total — 245 in the SOK583A1 group and 240 in the Eylea EU group. Both medicines are versions of aflibercept (40 mg/mL), an injection used in the eye for a condition called neovascular age-related macular degeneration (nAMD), which affects central vision. The trial was designed to compare the two treatments across a range of measures, including vision sharpness, changes in the layers of the eye, and the body's immune response to the medicine. Most participants completed the study (216 in the...
Read the full trial page · View reported results on ClinicalTrials.gov ↗
-
NCT04005352 · results posted 30 January 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04005352) enrolled 734 people in total — 366 received brolucizumab 6 mg and 368 received aflibercept 2 mg. Both are injected eye treatments used for a retinal eye condition. The trial was measuring how long doctors could go between injections without seeing any signs of disease activity (such as fluid in the retina or changes in vision), as well as whether participants' vision scores changed over time. The reported data shows that when looking at injection intervals up to Week 32, more participants in the brolucizumab gro...
-
NCT04435366 · results posted 28 December 2023
According to the results reported on ClinicalTrials.gov, this trial involved people with geographic atrophy (GA) — a serious eye condition linked to age-related macular degeneration that causes permanent loss of sight. In the first year, 225 people received the study drug (avacincaptad pegol) and 223 received a sham (inactive) procedure. In the second year, the groups were reorganised: some participants continued or switched treatments, bringing the total across all groups to 392 people entering year two. The trial was primarily measuring how quickly the area of damaged tissue in the eye grew...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04480463 · results posted 10 October 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT04480463) compared two treatments for an eye condition: an investigational treatment called SCD411 and an existing treatment called aflibercept. A total of 288 people were assigned to each group — 576 participants in all. The trial's main focus was on measuring changes in vision, specifically how many letters participants could correctly read on a standardised eye chart (a common way to measure vision in eye studies). By the end of the study, 259 people in the SCD411 group and 256 in the aflibercept group had completed the...
-
NCT04423718 · results posted 6 September 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT04423718) involved three groups of participants receiving different dosing regimens of a medicine called aflibercept, which is an injection used in the eye. In total, 1,009 people started the main part of the study — 336 in the first group (standard dose every 8 weeks, then a higher dose in an extension phase), 335 in the second group (higher dose every 12 weeks), and 338 in the third group (higher dose every 16 weeks). The trial was primarily measuring changes in vision, using a standardised eye chart test called the ETDR...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03525613 · results posted 6 July 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT03525613) enrolled 637 people across four groups to study a treatment called pegcetacoplan for geographic atrophy (GA) — a form of progressive vision loss affecting the back of the eye. Participants were assigned to receive either pegcetacoplan injections once a month or every other month, or a sham (dummy) procedure on the same schedules. The main thing being measured was how much the area of damaged tissue in the eye grew over 12 months, with further measurements continuing to 24 months. Not all participants completed th...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03525600 · results posted 18 June 2023
According to the results reported on ClinicalTrials.gov, this trial enrolled 621 people across four groups. Participants received either pegcetacoplan injections once a month, pegcetacoplan injections every other month, a sham (dummy) procedure once a month, or a sham procedure every other month. The trial was measuring changes in the size of geographic atrophy (GA) lesions — areas of damage at the back of the eye — in people with a condition called GA, which is an advanced form of age-related macular degeneration. The trial also looked at reading speed, reading independence, and overall visio...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03066258 · results posted 16 May 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT03066258) enrolled 42 people across five groups (called cohorts), with 6 people in each of the first three cohorts and 12 in each of the last two. All participants had a condition affecting the back of the eye involving abnormal blood vessel growth. The trial was investigating a gene therapy called RGX-314, which was delivered directly into the eye. Most participants completed the study — 40 out of 42 finished, with one person in Cohort 1 and one in Cohort 5 not completing it. The trial was primarily measuring how many par...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04331730 · results posted 26 October 2022
According to the results reported on ClinicalTrials.gov, this trial (NCT04331730) enrolled 107 people in total across three groups. Thirty-six participants received a lower dose of an investigational oral tablet called AKST4290 (800 mg) alongside a standard eye injection called aflibercept, 35 received a higher dose of AKST4290 (1600 mg) with aflibercept, and 36 received a placebo (dummy tablet) with aflibercept. The trial was primarily measuring changes in vision over time, using a standard eye-chart test called the ETDRS chart, where scores range from 0 to 93 and a higher score means better...
-
NCT03823300 · results posted 4 May 2022
According to the results reported on ClinicalTrials.gov, this trial (NCT03823300) enrolled 331 people in the faricimab group and 327 people in the aflibercept group — a total of 658 participants. Both faricimab and aflibercept are medicines given by injection into the eye and are used for a type of vision problem affecting the retina (the light-sensitive layer at the back of the eye). The trial's main goal was to measure changes in participants' best corrected visual acuity — that is, the sharpest vision a person can achieve with glasses or contact lenses — over the course of the study, using...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03150589 · results posted 21 May 2021
According to the results reported on ClinicalTrials.gov, this trial compared two medicines — SB11 (a proposed biosimilar, meaning a medicine designed to be very similar to an already-approved medicine) and Lucentis (ranibizumab, the reference medicine) — in people with a condition affecting vision. A total of 351 people were assigned to the SB11 group and 354 to the Lucentis group. The trial measured two things: changes in how well participants could read letters on a vision chart (called Best Corrected Visual Acuity, or BCVA), and changes in the thickness of a specific layer at the back of th...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03869684 · results posted 20 April 2021
According to the results reported on ClinicalTrials.gov, this trial (NCT03869684) involved 13 participants across three groups: 3 people received a placebo (inactive treatment), 5 received a low dose of MT-0814, and 5 received a high dose of MT-0814. The trial was looking at an eye condition and measuring two things: how well participants could read letters on an eye chart (known as best-corrected visual acuity), and the thickness of a specific layer at the centre of the retina (the back of the eye), measured using a scanning technology called optical coherence tomography. Of the 13 who starte...
-
NCT02540954 · results posted 8 April 2021
According to the results reported on ClinicalTrials.gov, this trial enrolled 168 people in each of two groups — 336 participants in total — all of whom had an eye condition being treated with a medicine called aflibercept. One group received injections on a flexible, extended schedule (meaning the time between injections could be stretched out based on how each person's eye was responding), while the other group received injections on a fixed schedule of once every eight weeks. The trial's main goal was to measure any change in how many letters participants could read on a standardised eye cha...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03794752 · results posted 5 January 2021
According to the results reported on ClinicalTrials.gov, this trial enrolled 8 participants, all of whom completed the study with none dropping out. All participants had low vision caused by either Age-related Macular Degeneration or Diabetic Macular Oedema — two conditions that can cause significant loss of central vision. The trial was a single-visit study, lasting approximately 1.5 hours per person, and looked at how participants performed on a range of vision tasks while wearing a head-mounted electronic visual enhancement device (essentially a wearable device designed to magnify or enhanc...
-
NCT03038880 · results posted 5 January 2021
According to the results reported on ClinicalTrials.gov, this trial (NCT03038880) enrolled 71 participants in total across three groups. Twenty-four people received faricimab (6 mg) by injection every 12 weeks, 31 received faricimab (6 mg) every 16 weeks, and 16 received ranibizumab (0.5 mg) every 4 weeks — a medicine already in use that served as a comparison group. The trial was measuring changes in vision over time, specifically how many letters participants could read on a standardised eye chart (called an ETDRS chart, scored from 0 to 100, where a higher score means better vision). Six pa...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT01485588 · results posted 6 November 2020
According to the results reported on ClinicalTrials.gov, this trial (NCT01485588) tested a treatment called hI-con1™, given as a single injection into the eye, across three different dose levels: 60 micrograms, 150 micrograms, and 300 micrograms. Six people were enrolled in each dose group, making 18 participants in total, and all 18 completed the study. The trial was measuring changes in two things over 24 weeks: the thickness of a central layer at the back of the eye (called the central retinal subfield thickness, measured using a scanning technology known as OCT), and the ability to read le...
See all 77 reported results for Macular Degeneration
These are the results as reported to the registry, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
What is coming
AI generated pipeline summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to NIH funding data, a substantial amount of public research funding has been directed toward macular degeneration in the United States. However, the direction of that funding has been falling year on year, which suggests that government investment in this area may be contracting rather than growing. For patients, this could mean that the pace of publicly funded discovery research may sl...
See the full Macular Degeneration page
Not medical advice. Voxsanity republishes public government health data in plain English. These figures describe research and registry activity, not the suitability of any treatment for any person. Trial status can change; always verify current status directly with the trial site and confirm Australian availability with your doctor.